Abstract:The use of drug combinations in clinical trials is increasingly common during the last years since a more favorable therapeutic response may be obtained by combining drugs. In phase I clinical trials, most of the existing methodology recommends a one unique dose combination as "optimal", which may result in a subsequent failed phase II clinical trial since other dose combinations may present higher treatment efficacy for the same level of toxicity. We are particularly interested in the setting where it is necessary to wait a few cycles of therapy to observe an efficacy outcome and the phase I and II population of patients are different with respect to treatment efficacy. Under these circumstances, it is common practice to implement two-stage designs where a set of maximum tolerated dose combinations is selected in a first stage, and then studied in a second stage for treatment efficacy. In this article we present a new two-stage design for early phase clinical trials with drug combinations. In the first stage, binary toxicity data is used to guide the dose escalation and set the maximum tolerated dose combinations. In the second stage, we take the set of maximum tolerated dose combinations recommended from the first stage, which remains fixed along the entire second stage, and through adaptive randomization, we allocate subsequent cohorts of patients in dose combinations that are likely to have high posterior median time to progression. The methodology is assessed with extensive simulations and exemplified with a real trial.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to design a method that can effectively evaluate the maximum tolerated dose (MTD) of drug combinations and their treatment effects in cancer clinical trials, especially when there are differences in treatment effects between patient groups in phase 1 and phase 2. Specifically, the paper proposes a new two - stage Bayesian seamless design method for drug combination research in early - stage clinical trials. This method aims to: 1. **Phase 1**: Use binary toxicity data to guide dose escalation and determine the maximum tolerated dose combination (MTD). This phase mainly focuses on safety, ensuring that the selected dose combination does not cause excessive toxicity. 2. **Phase 2**: Based on the maximum tolerated dose combination determined in phase 1, adaptively randomize subsequent patients to dose combinations that may have a higher posterior median time - to - progression (TTP). This phase focuses on efficacy, especially for those dose combinations that may have higher efficacy at the same toxicity level. The paper particularly emphasizes that in some cases, a single maximum tolerated dose combination may not be the optimal choice because there may be other dose combinations with the same toxicity level but different efficacies. Therefore, this design aims to explore multiple possible dose combinations to find the most effective treatment regimen. In addition, this design also takes into account the differences between patient groups between phase 1 and phase 2, and the fact that efficacy results can only be observed after multiple treatment cycles.

A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

Bayesian phase I/II adaptively randomized oncology trials with combined drugs

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

A Bayesian design for dual-agent dose optimization with targeted therapies

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

A Nonparametric Bayesian Design for Drug Combination Cancer Trials

Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints

A Bayesian Phase I/II Trial Design for Immunotherapy

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies.

Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes